PEN

As of 2026-10-26, PEN scores 41out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. PEN trades at $325.22, 123% above the band ceiling.

PEN scores 41 out of 100 on QNTM's five-factor model — a low-conviction reading — at 41 the factor profile is among the weaker names in the universe. Its strongest factor is volume at 55 (solid), where trading volume confirms genuine accumulation, followed by sentiment at 49. The weakest is value at 35, where valuation looks stretched. Among Healthcare stocks it sits in the lower 18% of Healthcare names by composite.

On valuation, PEN is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 41. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on PEN, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where PEN sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for PEN runs $124.50–$146.15. Current price $325.22 sits 123% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.